Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.64 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095533 | 0.90 | DRD4 (0.56) | DRD4GRM2NPC1GAAHTR1A | |
| SCHEMBL6874013 | 0.87 | DRD4 (0.56) | DRD4GRM2NPC1GAAHTR1A | |
| SCHEMBL6096279 | 0.79 | DRD4 (0.76) | DRD4GRM2MAPTDRD2 | |
| SCHEMBL6095609 | 0.76 | HTT (0.49) | DRD4NPC1GAAHTTCACNA1G | |
| SCHEMBL6787298 | 0.76 | DRD4 (1.00) | DRD4NPC1GAAHTR1AADRA2C | |
| SCHEMBL23964164 | 0.75 | DRD4 (0.68) | DRD4GRM2NPC1GAAHTR1A | |
| SCHEMBL4809921 | 0.75 | DRD4 (1.00) | DRD4GRM2NPC1GAAHTR1A | |
| SCHEMBL23964171 | 0.74 | DRD4 (0.82) | DRD4GRM2NPC1GAAHTR1A | |
| SCHEMBL21083242 | 0.74 | CYP1A2 (0.74) | HTR2ALMNAMAPTKCNH2 | |
| SCHEMBL29368403 | 0.74 | CYP1A2 (0.74) | HTR2ALMNAMAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | claimed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2002092575-A1 | BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2002092575-A1 | BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885GRM2 4337/4885NPC1 1050/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885GRM2 4337/4885NPC1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.